allopurinol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
124 315-30-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • zyloprim
  • allopurinol
  • tautomeric mixture of 1H-pyrazolo[3,4-d]pyrimidin-4-ol and 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
  • allopurinol sodium
A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.
  • Molecular weight: 136.11
  • Formula: C5H4N4O
  • CLOGP: 0.63
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 2
  • TPSA: 74.69
  • ALOGS: -0.79
  • ROTB: 0

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.40 g O
0.40 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.57 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 12 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 97.71 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 53 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.58 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 11 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.97 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 19, 1966 FDA PROMETHEUS LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 1776.82 10.13 987 100640 28561 46555874
Acute kidney injury 586.89 10.13 1463 100164 234392 46350043
Drug ineffective 409.39 10.13 528 101099 677310 45907125
Toxic epidermal necrolysis 336.44 10.13 322 101305 21956 46562479
Stevens-Johnson syndrome 322.40 10.13 321 101306 22976 46561459
Febrile neutropenia 276.68 10.13 626 101001 94001 46490434
Renal failure 271.49 10.13 695 100932 112899 46471536
Anaemia 269.56 10.13 1186 100441 254593 46329842
Rheumatoid arthritis 261.70 10.13 98 101529 240117 46344318
Gout 243.01 10.13 200 101427 11156 46573279
Tumour lysis syndrome 222.15 10.13 158 101469 7078 46577357
Hyperkalaemia 205.48 10.13 384 101243 50325 46534110
Rash maculo-papular 183.59 10.13 263 101364 27611 46556824
Pancytopenia 178.38 10.13 496 101131 84562 46499873
Completed suicide 171.89 10.13 52 101575 145868 46438567
Melaena 168.38 10.13 252 101375 27520 46556915
Cardiac failure 149.06 10.13 447 101180 79501 46504934
Renal impairment 147.42 10.13 425 101202 73947 46510488
Pain 145.15 10.13 542 101085 476406 46108029
Thrombocytopenia 143.76 10.13 601 101026 125980 46458455
Hyperuricaemia 142.50 10.13 102 101525 4615 46579820
Blood creatinine increased 137.57 10.13 422 101205 75981 46508454
General physical health deterioration 132.48 10.13 551 101076 115218 46469217
Cytokine release syndrome 119.53 10.13 103 101524 6120 46578315
Atrial fibrillation 116.91 10.13 491 101136 103099 46481336
Exposure during pregnancy 114.60 10.13 46 101581 108166 46476269
Sepsis 112.62 10.13 589 101038 135425 46449010
Platelet count decreased 108.15 10.13 468 101159 99556 46484879
Treatment failure 102.85 10.13 37 101590 93050 46491385
Haemoglobin decreased 101.68 10.13 551 101076 128398 46456037
Bradycardia 101.07 10.13 346 101281 65952 46518483
Pyrexia 100.42 10.13 1180 100447 347622 46236813
Drug hypersensitivity 99.11 10.13 242 101385 243583 46340852
Drug interaction 98.76 10.13 768 100859 202326 46382109
Maternal exposure during pregnancy 97.08 10.13 51 101576 102498 46481937
Headache 94.04 10.13 633 100994 477719 46106716
International normalised ratio increased 90.05 10.13 265 101362 46618 46537817
Neutropenic sepsis 89.65 10.13 122 101505 12202 46572233
Injection site pain 89.25 10.13 62 101565 107090 46477345
Toxic skin eruption 87.66 10.13 121 101506 12266 46572169
Dehydration 86.40 10.13 619 101008 158921 46425514
Chronic kidney disease 86.25 10.13 239 101388 40632 46543803
Lactic acidosis 85.58 10.13 212 101415 33697 46550738
Pemphigus 85.12 10.13 3 101624 45271 46539164
Plasma cell myeloma 82.20 10.13 248 101379 44230 46540205
Joint swelling 81.56 10.13 148 101479 165925 46418510
Therapeutic product effect decreased 81.30 10.13 39 101588 82562 46501873
Off label use 77.91 10.13 496 101131 379345 46205090
Eosinophilia 77.13 10.13 145 101482 19072 46565363
Intentional overdose 76.68 10.13 23 101604 64921 46519514
Blood urea increased 76.52 10.13 170 101457 25182 46559253
Neutropenia 76.01 10.13 553 101074 142651 46441784
Blood uric acid increased 75.59 10.13 67 101560 4134 46580301
Anxiety 74.36 10.13 180 101447 181777 46402658
Arthralgia 73.79 10.13 478 101149 364125 46220310
Product prescribing error 72.80 10.13 145 101482 19902 46564533
Injection site erythema 71.94 10.13 36 101591 74391 46510044
Hypotension 71.34 10.13 797 100830 231792 46352643
Depression 65.83 10.13 173 101454 169931 46414504
Drug intolerance 65.31 10.13 139 101488 146910 46437525
Alopecia 65.30 10.13 162 101465 162252 46422183
Contraindicated product administered 64.28 10.13 48 101579 79899 46504536
Gastrointestinal haemorrhage 61.87 10.13 332 101295 77041 46507394
Dilatation intrahepatic duct acquired 61.66 10.13 31 101596 725 46583710
Systemic lupus erythematosus 60.81 10.13 33 101594 65147 46519288
Oedema peripheral 60.22 10.13 571 101056 159135 46425300
Hand deformity 59.55 10.13 4 101623 34570 46549865
Acute myeloid leukaemia 57.15 10.13 114 101513 15664 46568771
Arthropathy 57.10 10.13 60 101567 84640 46499795
Abdominal discomfort 56.77 10.13 156 101471 151009 46433426
Glossodynia 55.59 10.13 14 101613 44359 46540076
Haematoma 55.42 10.13 174 101453 31698 46552737
Multiple sclerosis relapse 55.33 10.13 12 101615 42113 46542322
Abortion spontaneous 54.23 10.13 14 101613 43632 46540803
Toxicity to various agents 54.02 10.13 257 101370 211509 46372926
Injection site reaction 51.19 10.13 20 101607 47829 46536606
Injection site pruritus 50.84 10.13 12 101615 39731 46544704
Hypokalaemia 50.80 10.13 347 101280 87677 46496758
Drug abuse 49.78 10.13 39 101588 63369 46521066
Tubulointerstitial nephritis 49.01 10.13 103 101524 14685 46569750
Therapeutic product effect incomplete 48.71 10.13 59 101568 78094 46506341
Dermatitis exfoliative 48.43 10.13 61 101566 5655 46578780
Cardioactive drug level increased 47.71 10.13 38 101589 2021 46582414
Nasopharyngitis 45.95 10.13 176 101451 153822 46430613
Suicidal ideation 45.13 10.13 34 101593 56348 46528087
Hyponatraemia 44.70 10.13 375 101252 100957 46483478
Face oedema 44.42 10.13 116 101511 19037 46565398
Blood lactate dehydrogenase increased 44.35 10.13 121 101506 20379 46564056
Sopor 43.87 10.13 118 101509 19710 46564725
Splenomegaly 43.82 10.13 77 101550 9611 46574824
Labelled drug-drug interaction medication error 43.58 10.13 74 101553 8987 46575448
Injection site swelling 42.90 10.13 17 101610 40310 46544125
Tumour flare 42.53 10.13 18 101609 279 46584156
Chronic lymphocytic leukaemia 42.03 10.13 41 101586 2859 46581576
Allergic reaction to excipient 41.29 10.13 18 101609 301 46584134
Pneumonia 41.17 10.13 1091 100536 375229 46209206
Epistaxis 40.42 10.13 259 101368 64046 46520389
Sinusitis 40.21 10.13 146 101481 129622 46454813
Skin exfoliation 40.17 10.13 160 101467 32778 46551657
Seizure 39.09 10.13 137 101490 122917 46461518
Blast crisis in myelogenous leukaemia 39.01 10.13 20 101607 488 46583947
Shock haemorrhagic 38.31 10.13 68 101559 8556 46575879
Psoriasis 37.70 10.13 71 101556 78533 46505902
Asthenia 37.57 10.13 914 100713 310161 46274274
Hypoglycaemia 37.36 10.13 224 101403 54125 46530310
Rash morbilliform 37.14 10.13 39 101588 2970 46581465
Suicide attempt 37.07 10.13 39 101588 54997 46529438
Inappropriate schedule of product administration 36.51 10.13 53 101574 64960 46519475
Injection site bruising 36.33 10.13 16 101611 35620 46548815
Mucosal inflammation 35.86 10.13 174 101453 38802 46545633
Breast cancer 35.72 10.13 28 101599 45490 46538945
Dialysis 35.33 10.13 72 101555 10044 46574391
Purpura 34.93 10.13 71 101556 9887 46574548
Product use issue 34.53 10.13 99 101528 94545 46489890
Intentional product misuse 34.52 10.13 31 101596 47097 46537338
Multiple organ dysfunction syndrome 34.19 10.13 211 101416 51499 46532936
Rheumatoid factor positive 33.46 10.13 3 101624 20458 46563977
Fatigue 33.29 10.13 1041 100586 607656 45976779
Pregnancy 33.15 10.13 9 101618 27128 46557307
Sinoatrial block 32.60 10.13 21 101606 797 46583638
Acute motor-sensory axonal neuropathy 32.47 10.13 16 101611 358 46584077
Pleural effusion 32.43 10.13 299 101328 82653 46501782
Insomnia 32.36 10.13 218 101409 164706 46419729
Migraine 32.07 10.13 65 101562 69961 46514474
Loss of personal independence in daily activities 31.73 10.13 47 101580 57136 46527299
Synovitis 31.24 10.13 53 101574 61022 46523413
HLA-B*5801 assay positive 30.79 10.13 6 101621 0 46584435
Differentiation syndrome 30.54 10.13 21 101606 890 46583545
Product dose omission issue 30.50 10.13 228 101399 168292 46416143
Sight disability 30.23 10.13 11 101616 111 46584324
Thermohypoaesthesia 30.14 10.13 11 101616 112 46584323
Respiratory failure 29.94 10.13 327 101300 94489 46489946
Intentional self-injury 29.55 10.13 8 101619 24158 46560277
Foetal exposure during pregnancy 29.51 10.13 15 101612 30732 46553703
Feeling abnormal 29.44 10.13 156 101471 124904 46459531
Throat irritation 29.43 10.13 13 101614 28888 46555547
Product quality issue 29.17 10.13 21 101606 35627 46548808
Device dislocation 29.06 10.13 6 101621 21796 46562639
Human herpesvirus 6 infection 29.01 10.13 31 101596 2408 46582027
Hypersensitivity 28.84 10.13 200 101427 150121 46434314
White blood cell count decreased 28.80 10.13 372 101255 111859 46472576
Azotaemia 28.55 10.13 41 101586 4310 46580125
Rectal haemorrhage 28.45 10.13 161 101466 38094 46546341
Lip erosion 28.17 10.13 19 101608 780 46583655
Right ventricular failure 28.10 10.13 88 101539 16005 46568430
Fibromyalgia 27.90 10.13 23 101604 36440 46547995
Psoriatic arthropathy 27.77 10.13 23 101604 36356 46548079
Rhabdomyolysis 27.70 10.13 171 101456 41738 46542697
Diarrhoea 27.46 10.13 1484 100143 558118 46026317
Sleep disorder 27.41 10.13 37 101590 46758 46537677
Metabolic acidosis 27.39 10.13 161 101466 38619 46545816
Glomerular filtration rate decreased 27.29 10.13 71 101556 11623 46572812
Electrolyte imbalance 27.19 10.13 91 101536 17135 46567300
Rash erythematous 27.17 10.13 147 101480 34203 46550232
Hypercalcaemia 27.09 10.13 104 101523 20942 46563493
Dermatitis exfoliative generalised 26.88 10.13 33 101594 2980 46581455
Anaemia macrocytic 26.87 10.13 31 101596 2622 46581813
Infusion related reaction 26.85 10.13 121 101506 101087 46483348
Enanthema 26.57 10.13 15 101612 446 46583989
Agranulocytosis 26.43 10.13 107 101520 22078 46562357
Subdural haematoma 26.42 10.13 75 101552 12922 46571513
Klebsiella infection 26.40 10.13 50 101577 6612 46577823
Blood creatine phosphokinase increased 26.39 10.13 125 101502 27599 46556836
Alanine aminotransferase increased 26.09 10.13 301 101326 88150 46496285
Pemphigoid 25.44 10.13 45 101582 5646 46578789
Wrong technique in product usage process 25.36 10.13 50 101577 54372 46530063
Chemical burn of oral cavity 25.26 10.13 9 101618 85 46584350
Anuria 25.25 10.13 68 101559 11363 46573072
Oral mucosa erosion 25.01 10.13 20 101607 1070 46583365
Discomfort 24.33 10.13 40 101587 46630 46537805
Septic shock 24.33 10.13 212 101415 57681 46526754
Hyperpyrexia 24.20 10.13 30 101597 2736 46581699
Erythema multiforme 23.77 10.13 60 101567 9644 46574791
Petechiae 23.73 10.13 71 101556 12599 46571836
Disseminated intravascular coagulation 23.72 10.13 93 101534 18912 46565523
Haemodialysis 23.64 10.13 58 101569 9159 46575276
Coagulation test abnormal 23.63 10.13 16 101611 661 46583774
Leukopenia 23.59 10.13 240 101387 68103 46516332
Gastrointestinal disorder 23.46 10.13 60 101567 59516 46524919
Asthma 23.36 10.13 111 101516 91431 46493004
Intentional product use issue 23.31 10.13 50 101577 52730 46531705
Paraesthesia 23.14 10.13 155 101472 117282 46467153
Abdominal pain upper 22.90 10.13 204 101423 145101 46439334
Dermatitis bullous 22.77 10.13 51 101576 7592 46576843
Multiple sclerosis 22.47 10.13 13 101614 24778 46559657
Platelet disorder 22.47 10.13 22 101605 1541 46582894
Cerebellar stroke 22.42 10.13 10 101617 177 46584258
Oedema 22.42 10.13 234 101393 66837 46517598
Accidental exposure to product 22.24 10.13 9 101618 21072 46563363
Papillary muscle rupture 22.21 10.13 5 101622 5 46584430
Dyspnoea 22.13 10.13 1351 100276 514197 46070238
Hypovolaemic shock 21.91 10.13 40 101587 5143 46579292
Injection site rash 21.82 10.13 4 101623 15809 46568626
Necrotising ulcerative gingivostomatitis 21.81 10.13 6 101621 21 46584414
Eosinopenia 21.73 10.13 5 101622 6 46584429
Mucosal ulceration 21.68 10.13 17 101610 884 46583551
No adverse event 21.15 10.13 26 101601 34205 46550230
Osteoarthritis 21.09 10.13 67 101560 61958 46522477
Hypoaesthesia 20.94 10.13 162 101465 118707 46465728
Abdominal wall wound 20.78 10.13 7 101620 55 46584380
Syncope 20.75 10.13 332 101295 104471 46479964
Vessel puncture site haemorrhage 20.67 10.13 8 101619 97 46584338
Hyperglycaemia 20.66 10.13 139 101488 34932 46549503
Hyperphosphataemia 20.64 10.13 22 101605 1704 46582731
Administration site discomfort 20.38 10.13 8 101619 101 46584334
Injection site mass 20.33 10.13 4 101623 15036 46569399
Hip arthroplasty 20.33 10.13 7 101620 18105 46566330
Drug withdrawal syndrome 20.06 10.13 18 101609 27366 46557069
Injection site haemorrhage 20.03 10.13 10 101617 20699 46563736
Blood pressure fluctuation 20.03 10.13 22 101605 30426 46554009
Pericardial effusion 19.99 10.13 109 101518 25434 46559001
Blood pressure increased 19.88 10.13 178 101449 126488 46457947
Arrhythmia 19.87 10.13 137 101490 34704 46549731
Cardiac failure acute 19.84 10.13 50 101577 8028 46576407
Conjunctivitis 19.67 10.13 76 101551 15348 46569087
Renal disorder 19.63 10.13 112 101515 26574 46557861
Lip oedema 19.63 10.13 30 101597 3334 46581101
Swelling 19.53 10.13 175 101452 124336 46460099
Hypoglycaemic coma 19.51 10.13 26 101601 2548 46581887
Amaurosis 19.51 10.13 13 101614 523 46583912
Stress 19.48 10.13 53 101574 51498 46532937
Back pain 19.37 10.13 331 101296 209708 46374727
Transfusion 19.23 10.13 68 101559 13163 46571272
Hepatitis 19.17 10.13 128 101499 32087 46552348
Mandibular mass 19.09 10.13 9 101618 182 46584253
Mucosal erosion 18.84 10.13 19 101608 1379 46583056
Blood potassium increased 18.78 10.13 80 101547 16887 46567548
Acute respiratory failure 18.70 10.13 118 101509 29020 46555415
Tonsillar haemorrhage 18.65 10.13 9 101618 192 46584243
Hepatocellular injury 18.60 10.13 119 101508 29403 46555032
Myeloblast percentage decreased 18.53 10.13 6 101621 41 46584394
Heart rate increased 18.32 10.13 92 101535 74699 46509736
Pseudomonal bacteraemia 18.24 10.13 18 101609 1273 46583162
Terminal ileitis 18.07 10.13 8 101619 139 46584296
Drug eruption 18.04 10.13 93 101534 21236 46563199
Diverticulum oesophageal 18.02 10.13 8 101619 140 46584295
Fluid overload 18.01 10.13 111 101516 27074 46557361
Influenza 17.99 10.13 117 101510 89153 46495282
Ecchymosis 17.70 10.13 57 101570 10519 46573916
Diabetes mellitus inadequate control 17.59 10.13 66 101561 13148 46571287
Musculoskeletal stiffness 17.51 10.13 133 101494 97860 46486575
Atrioventricular block complete 17.49 10.13 46 101581 7581 46576854
Tachyarrhythmia 17.41 10.13 34 101593 4598 46579837
Blood alkaline phosphatase increased 17.14 10.13 146 101481 39463 46544972
Renal infarct 17.14 10.13 17 101610 1210 46583225
Therapeutic drug monitoring analysis incorrectly performed 17.10 10.13 8 101619 159 46584276
Cerebral haemorrhage 17.04 10.13 113 101514 28258 46556177
Glomerulonephritis 16.98 10.13 19 101608 1554 46582881
Urine output decreased 16.96 10.13 58 101569 11039 46573396
Hypocalcaemia 16.89 10.13 108 101519 26677 46557758
Red blood cell sedimentation rate increased 16.82 10.13 15 101612 22874 46561561
Arthritis 16.79 10.13 99 101528 77217 46507218
Neutrophil count decreased 16.70 10.13 156 101471 43270 46541165
Cholestasis 16.69 10.13 108 101519 26785 46557650
Poisoning 16.43 10.13 5 101622 13989 46570446
Anger 16.35 10.13 3 101624 11849 46572586
Pain in extremity 16.16 10.13 434 101193 258246 46326189
B-cell unclassifiable lymphoma high grade 16.15 10.13 4 101623 8 46584427
Streptococcal sepsis 16.10 10.13 19 101608 1646 46582789
Multimorbidity 16.10 10.13 13 101614 705 46583730
Mantle cell lymphoma 16.08 10.13 12 101615 579 46583856
Metastases to bone 16.07 10.13 9 101618 17467 46566968
Lymphocytosis 16.07 10.13 22 101605 2212 46582223
Pericarditis 16.06 10.13 17 101610 23910 46560525
Aplasia pure red cell 16.05 10.13 32 101595 4393 46580042
Acute generalised exanthematous pustulosis 16.03 10.13 51 101576 9354 46575081
Pulmonary oedema 16.01 10.13 176 101451 50929 46533506
Cardiac failure chronic 15.93 10.13 28 101599 3496 46580939
Hypersensitivity vasculitis 15.89 10.13 31 101596 4190 46580245
Influenza like illness 15.76 10.13 68 101559 57502 46526933
Medication error 15.58 10.13 118 101509 30793 46553642
Nephrogenic anaemia 15.55 10.13 20 101607 1893 46582542
Performance enhancing product use 15.54 10.13 4 101623 10 46584425
Limb discomfort 15.49 10.13 16 101611 22760 46561675
Hyperbilirubinaemia 15.47 10.13 54 101573 10384 46574051
Eye pain 15.46 10.13 23 101604 27917 46556518
Gouty arthritis 15.40 10.13 11 101616 496 46583939
Emphysematous cystitis 15.39 10.13 7 101620 130 46584305
Anti-neutrophil cytoplasmic antibody positive vasculitis 15.37 10.13 20 101607 1915 46582520
Generalised tonic-clonic seizure 15.33 10.13 22 101605 27100 46557335
Dizziness 15.32 10.13 596 101031 339818 46244617
Packed red blood cell transfusion 15.11 10.13 21 101606 2142 46582293
Hepatic enzyme increased 15.09 10.13 110 101517 81677 46502758
Product monitoring error 15.00 10.13 20 101607 1961 46582474
Respiratory arrest 14.96 10.13 32 101595 33784 46550651
Hepatic function abnormal 14.95 10.13 127 101500 34294 46550141
Neuroleptic malignant syndrome 14.95 10.13 3 101624 11119 46573316
Gravitational oedema 14.92 10.13 15 101612 1085 46583350
Paraneoplastic syndrome 14.88 10.13 11 101616 523 46583912
Bone marrow failure 14.81 10.13 113 101514 29556 46554879
Uveitic glaucoma 14.77 10.13 4 101623 13 46584422
Dyspnoea exertional 14.76 10.13 171 101456 50118 46534317
Ear infection 14.73 10.13 17 101610 22996 46561439
Nodal arrhythmia 14.72 10.13 16 101611 1267 46583168
Knee arthroplasty 14.59 10.13 18 101609 23647 46560788
Leukocytosis 14.54 10.13 94 101533 23304 46561131
Venoocclusive liver disease 14.54 10.13 30 101597 4221 46580214
Autoimmune haemolytic anaemia 14.51 10.13 30 101597 4228 46580207
Chronic myeloid leukaemia 14.46 10.13 22 101605 2436 46581999
Staphylococcal scalded skin syndrome 14.44 10.13 7 101620 151 46584284
Burning sensation 14.39 10.13 49 101578 44362 46540073
Haemoperitoneum 14.30 10.13 22 101605 2460 46581975
Diabetic hyperosmolar coma 14.21 10.13 10 101617 440 46583995
Erosive oesophagitis 14.19 10.13 18 101609 1680 46582755
Cholestatic liver injury 14.17 10.13 20 101607 2070 46582365
Complication associated with device 14.13 10.13 8 101619 15433 46569002
Orthopnoea 14.03 10.13 36 101591 5844 46578591
Upper respiratory tract infection 14.00 10.13 81 101546 63475 46520960
Parakeratosis 13.99 10.13 7 101620 162 46584273
Ill-defined disorder 13.97 10.13 23 101604 26804 46557631
Blood uric acid abnormal 13.96 10.13 5 101622 48 46584387
Duodenal stenosis 13.88 10.13 11 101616 581 46583854
Hepatic failure 13.84 10.13 122 101505 33294 46551141
Cholecystitis chronic 13.77 10.13 3 101624 10496 46573939
Hypocoagulable state 13.69 10.13 14 101613 1033 46583402
Full blood count decreased 13.66 10.13 89 101538 22122 46562313
Acute myeloid leukaemia recurrent 13.62 10.13 16 101611 1380 46583055
Overdose 13.61 10.13 149 101478 101830 46482605
Lip haemorrhage 13.60 10.13 10 101617 472 46583963
Drug dependence 13.51 10.13 14 101613 19887 46564548
Haematocrit decreased 13.51 10.13 126 101501 34931 46549504
Hepatotoxicity 13.48 10.13 97 101530 24912 46559523
Dermatitis 13.48 10.13 64 101563 14144 46570291
Live birth 13.45 10.13 3 101624 10327 46574108
Drug-induced liver injury 13.45 10.13 98 101529 25270 46559165
Mucocutaneous haemorrhage 13.36 10.13 5 101622 55 46584380
Diabetic ketoacidosis 13.30 10.13 12 101615 18198 46566237
Serum ferritin increased 13.29 10.13 33 101594 5250 46579185
HLA marker study positive 13.29 10.13 7 101620 181 46584254
Cardiomegaly 13.27 10.13 74 101553 17408 46567027
Prerenal failure 13.24 10.13 16 101611 1421 46583014
Blood bilirubin increased 13.24 10.13 123 101504 34061 46550374
Neutropenic colitis 13.16 10.13 20 101607 2212 46582223
Irritability 13.14 10.13 27 101600 28919 46555516
Pulmonary arterial hypertension 13.08 10.13 99 101528 25829 46558606
Adult failure to thrive 13.07 10.13 6 101621 114 46584321
Somnolence 13.05 10.13 251 101376 156270 46428165
Foot fracture 13.04 10.13 14 101613 19568 46564867
Adverse event 13.02 10.13 35 101592 34149 46550286
Mixed liver injury 12.96 10.13 24 101603 3119 46581316
Vision blurred 12.95 10.13 111 101516 79597 46504838
Aspartate aminotransferase increased 12.93 10.13 242 101385 78458 46505977
Panic attack 12.90 10.13 15 101612 20227 46564208
Lymphocytic infiltration 12.83 10.13 12 101615 794 46583641
Upper gastrointestinal haemorrhage 12.81 10.13 71 101556 16667 46567768
Oral contusion 12.75 10.13 5 101622 63 46584372
Insulin-requiring type 2 diabetes mellitus 12.75 10.13 5 101622 63 46584372
Chronic myeloid leukaemia recurrent 12.68 10.13 7 101620 199 46584236
Chronic lymphocytic leukaemia recurrent 12.68 10.13 7 101620 199 46584236
Pruritus 12.67 10.13 647 100980 241705 46342730
Electrocardiogram QT shortened 12.61 10.13 6 101621 124 46584311
Shock 12.52 10.13 86 101541 21759 46562676
Nasal mucosal erosion 12.47 10.13 5 101622 67 46584368
Trichiasis 12.40 10.13 5 101622 68 46584367
Eosinophilic pustular folliculitis 12.40 10.13 4 101623 27 46584408
Sternal fracture 12.31 10.13 16 101611 1530 46582905
Blood phosphorus increased 12.23 10.13 22 101605 2797 46581638
Venoocclusive disease 12.21 10.13 18 101609 1938 46582497
Deficiency anaemia 12.11 10.13 3 101624 6 46584429
Fixed eruption 12.11 10.13 12 101615 853 46583582
Gastritis erosive 12.07 10.13 32 101595 5298 46579137
Injury 12.05 10.13 52 101575 43975 46540460
Withdrawal syndrome 12.04 10.13 13 101614 18121 46566314
Drug resistance 12.04 10.13 12 101615 17356 46567079
Eye oedema 12.00 10.13 15 101612 1380 46583055
Ileal ulcer 11.99 10.13 9 101618 438 46583997
Conjunctival hyperaemia 11.98 10.13 18 101609 1971 46582464
Spontaneous haematoma 11.98 10.13 11 101616 711 46583724
Retroperitoneal haematoma 11.96 10.13 21 101606 2619 46581816
Weight decreased 11.83 10.13 359 101268 210490 46373945
Procedural pain 11.82 10.13 7 101620 13172 46571263
Extensor plantar response 11.78 10.13 14 101613 1222 46583213
Musculoskeletal disorder 11.65 10.13 10 101617 15535 46568900
Chest discomfort 11.61 10.13 133 101494 90136 46494299
Proteus test positive 11.61 10.13 6 101621 149 46584286
Blood electrolytes increased 11.60 10.13 4 101623 34 46584401
Multiple drug therapy 11.59 10.13 12 101615 899 46583536
Strangury 11.52 10.13 3 101624 8 46584427
Disturbance in attention 11.51 10.13 33 101594 31527 46552908
Device issue 11.50 10.13 16 101611 19964 46564471
Abnormal dreams 11.49 10.13 4 101623 10275 46574160
Prurigo 11.49 10.13 12 101615 908 46583527
Aggression 11.39 10.13 20 101607 22724 46561711
Surgery 11.32 10.13 29 101598 28756 46555679
Depressed mood 11.32 10.13 36 101591 33283 46551152
Weight increased 11.32 10.13 272 101355 164201 46420234
Spigelian hernia 11.30 10.13 4 101623 37 46584398
Epidermolysis 11.30 10.13 7 101620 248 46584187
Pulmonary hypertension 11.29 10.13 124 101503 35869 46548566
Nephropathy 11.28 10.13 30 101597 4975 46579460
Calciphylaxis 11.27 10.13 20 101607 2515 46581920
Therapeutic drug monitoring analysis not performed 11.26 10.13 9 101618 481 46583954
Psychotic disorder 11.23 10.13 20 101607 22601 46561834
Visual impairment 11.22 10.13 92 101535 66597 46517838
Cardiac failure congestive 11.15 10.13 270 101357 91480 46492955
Respiratory tract congestion 11.14 10.13 7 101620 12757 46571678
Eosinophilic myocarditis 11.11 10.13 8 101619 365 46584070
Renal hypertension 11.11 10.13 4 101623 39 46584396
Halo vision 11.06 10.13 8 101619 368 46584067
Optic ischaemic neuropathy 11.03 10.13 12 101615 951 46583484
Neutropenic infection 11.03 10.13 13 101614 1125 46583310
Cardiac murmur functional 11.02 10.13 4 101623 40 46584395
Urosepsis 11.01 10.13 64 101563 15289 46569146
Rheumatoid nodule 11 10.13 3 101624 9017 46575418
Acid base balance abnormal 10.93 10.13 7 101620 263 46584172
Platelet dysfunction 10.89 10.13 5 101622 95 46584340
Transaminases increased 10.81 10.13 100 101527 27661 46556774
Meibomian gland dysfunction 10.75 10.13 5 101622 98 46584337
Bone marrow transplant 10.71 10.13 10 101617 660 46583775
Neuromyelitis optica spectrum disorder 10.70 10.13 11 101616 817 46583618
Rash pruritic 10.68 10.13 145 101482 44070 46540365
Serotonin syndrome 10.65 10.13 23 101604 24197 46560238
Blood pressure systolic increased 10.57 10.13 30 101597 28757 46555678
Emotional distress 10.56 10.13 33 101594 30674 46553761
Ear pain 10.55 10.13 20 101607 22072 46562363
Presyncope 10.50 10.13 90 101537 24364 46560071
Pseudomonal sepsis 10.50 10.13 17 101610 1985 46582450
Bradyarrhythmia 10.47 10.13 17 101610 1989 46582446
Throat tightness 10.47 10.13 18 101609 20621 46563814
Device breakage 10.45 10.13 4 101623 9688 46574747
Acne 10.45 10.13 17 101610 19902 46564533
Leukostasis syndrome 10.37 10.13 4 101623 48 46584387
Cough 10.37 10.13 403 101224 229846 46354589
Rhinorrhoea 10.37 10.13 61 101566 47604 46536831
Tooth infection 10.36 10.13 7 101620 12279 46572156
Left ventricular failure 10.34 10.13 29 101598 4961 46579474
Maternal condition affecting foetus 10.32 10.13 6 101621 189 46584246
Endocarditis 10.26 10.13 29 101598 4983 46579452
Aortic valve sclerosis 10.26 10.13 12 101615 1030 46583405
Hyperviscosity syndrome 10.23 10.13 6 101621 192 46584243
Hypozincaemia 10.22 10.13 3 101624 14 46584421
Crying 10.22 10.13 19 101608 21122 46563313
Head banging 10.20 10.13 8 101619 416 46584019
Schizophrenia 10.17 10.13 3 101624 8565 46575870
Muscle necrosis 10.16 10.13 9 101618 555 46583880
Joint stiffness 10.14 10.13 28 101599 27080 46557355

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug reaction with eosinophilia and systemic symptoms 1098.94 10.22 1076 174320 27412 29749670
Gout 380.62 10.22 488 174908 16827 29760255
Acute kidney injury 366.13 10.22 2796 172600 271046 29506036
Drug ineffective 358.29 10.22 929 174467 339458 29437624
Drug abuse 317.98 10.22 50 175346 82022 29695060
Toxicity to various agents 284.22 10.22 373 175023 176810 29600272
Tumour lysis syndrome 252.04 10.22 343 175053 12542 29764540
Completed suicide 204.94 10.22 169 175227 99323 29677759
Hyperkalaemia 163.13 10.22 792 174604 65218 29711864
Stevens-Johnson syndrome 156.65 10.22 329 175067 17227 29759855
Renal failure 152.42 10.22 1282 174114 127684 29649398
Off label use 144.72 10.22 862 174534 248428 29528654
Foetal exposure during pregnancy 141.51 10.22 23 175373 36848 29740234
Anaemia 138.23 10.22 1840 173556 206152 29570930
Hyperuricaemia 122.69 10.22 182 175214 7212 29769870
Eosinophilia 122.25 10.22 345 175051 21815 29755267
Febrile neutropenia 116.26 10.22 1042 174354 105651 29671431
Cardiac failure 111.37 10.22 853 174543 82565 29694517
Toxic epidermal necrolysis 100.61 10.22 281 175115 17659 29759423
Intentional overdose 87.15 10.22 69 175327 41412 29735670
Blood creatinine increased 83.47 10.22 860 174536 90515 29686567
Headache 82.65 10.22 677 174719 181629 29595453
Drug dependence 77.97 10.22 15 175381 21280 29755802
General physical health deterioration 77.23 10.22 910 174486 99034 29678048
Cytokine release syndrome 75.97 10.22 175 175221 9758 29767324
Product use in unapproved indication 75.59 10.22 203 175193 73490 29703592
Chronic kidney disease 73.51 10.22 425 174971 37413 29739669
Treatment failure 69.98 10.22 60 175336 34619 29742463
Suicide attempt 69.87 10.22 67 175329 36630 29740452
Blood uric acid increased 69.72 10.22 126 175270 5897 29771185
Chronic lymphocytic leukaemia 68.44 10.22 108 175288 4520 29772562
Death 67.89 10.22 1585 173811 355698 29421384
Renal impairment 66.57 10.22 770 174626 83414 29693668
Rheumatoid arthritis 65.58 10.22 87 175309 41110 29735972
Overdose 64.67 10.22 264 175132 84073 29693009
Seizure 63.76 10.22 328 175068 98147 29678935
Depression 62.72 10.22 294 175102 90143 29686939
Oedema peripheral 61.89 10.22 916 174480 104916 29672166
Dermatitis exfoliative generalised 61.29 10.22 79 175317 2736 29774346
Thrombocytopenia 60.58 10.22 1133 174263 135911 29641171
Toxic skin eruption 60.25 10.22 171 175225 10844 29766238
Drug withdrawal syndrome 59.13 10.22 21 175375 19788 29757294
Anxiety 58.94 10.22 298 175098 89573 29687509
Rash maculo-papular 58.48 10.22 299 175097 25119 29751963
Dermatitis exfoliative 55.52 10.22 130 175266 7326 29769756
Therapeutic product effect incomplete 55.34 10.22 70 175326 33764 29743318
Suicidal ideation 54.74 10.22 79 175317 36035 29741047
Premature baby 54.65 10.22 15 175381 16676 29760406
Aggression 53.74 10.22 83 175313 36824 29740258
Injection site pain 50.32 10.22 62 175334 30248 29746834
Pain 48.55 10.22 715 174681 171926 29605156
Drug resistance 48.25 10.22 29 175367 20104 29756978
Product dose omission issue 47.76 10.22 327 175069 91304 29685778
Blood lactate dehydrogenase increased 45.76 10.22 240 175156 20361 29756721
Melaena 45.08 10.22 335 175061 32102 29744980
Insomnia 44.81 10.22 341 175055 92995 29684087
Gouty arthritis 44.68 10.22 42 175354 1013 29776069
Epistaxis 44.29 10.22 490 174906 52491 29724591
Atrial fibrillation 44.03 10.22 883 174513 107241 29669841
Syncope 43.94 10.22 720 174676 84183 29692899
Face oedema 43.71 10.22 156 175240 11178 29765904
Intentional product misuse 43.18 10.22 86 175310 34581 29742501
Pyrexia 42.90 10.22 2121 173275 292368 29484714
Platelet count decreased 42.31 10.22 864 174532 105265 29671817
Drug intolerance 41.87 10.22 131 175265 45160 29731922
Hypotension 41.26 10.22 1498 173898 199067 29578015
Blood urea increased 40.76 10.22 319 175077 31062 29746020
Respiratory arrest 40.52 10.22 68 175328 29190 29747892
Cardio-respiratory arrest 40.47 10.22 185 175211 57121 29719961
Serotonin syndrome 39.84 10.22 28 175368 17863 29759219
Purpura 39.14 10.22 138 175258 9829 29767253
Sedation 38.65 10.22 24 175372 16349 29760733
Intentional product use issue 38.39 10.22 99 175297 36341 29740741
Neuroleptic malignant syndrome 38.31 10.22 24 175372 16271 29760811
Sepsis 36.88 10.22 1120 174276 145275 29631807
Asthma 36.80 10.22 100 175296 36074 29741008
Psychotic disorder 35.72 10.22 44 175352 21471 29755611
Gouty tophus 35.60 10.22 17 175379 121 29776961
Rhabdomyolysis 35.45 10.22 546 174850 63034 29714048
Neutropenic sepsis 34.97 10.22 146 175250 11263 29765819
Tumour flare 34.79 10.22 27 175369 497 29776585
Immune reconstitution inflammatory syndrome 34.20 10.22 6 175390 9095 29767987
Drug interaction 33.88 10.22 1460 173936 198108 29578974
Product monitoring error 33.51 10.22 46 175350 1695 29775387
Splenomegaly 32.71 10.22 161 175235 13319 29763763
Somnolence 32.17 10.22 387 175009 96376 29680706
Poisoning 30.81 10.22 14 175382 11368 29765714
Haemoglobin decreased 30.09 10.22 878 174518 113220 29663862
Multiple sclerosis relapse 29.97 10.22 13 175383 10849 29766233
Abnormal behaviour 29.05 10.22 67 175329 25556 29751526
Inappropriate schedule of product administration 28.80 10.22 127 175269 39601 29737481
Device interaction 28.30 10.22 22 175374 406 29776676
International normalised ratio increased 28.17 10.22 414 174982 47325 29729757
Acute myeloid leukaemia 27.94 10.22 191 175205 17815 29759267
Substance abuse 27.90 10.22 4 175392 7036 29770046
Intentional self-injury 27.80 10.22 23 175373 13509 29763573
Wrong technique in product usage process 27.48 10.22 92 175304 31063 29746019
Hypercreatininaemia 27.42 10.22 23 175373 475 29776607
Coma 27.14 10.22 133 175263 40316 29736766
Drug hypersensitivity 26.78 10.22 264 175132 68255 29708827
Synovitis 26.54 10.22 12 175384 9771 29767311
Hepatitis C 26.45 10.22 23 175373 13182 29763900
Irritability 26.35 10.22 60 175336 22990 29754092
Incorrect route of product administration 26.14 10.22 17 175379 11298 29765784
Blood potassium increased 25.17 10.22 172 175224 16041 29761041
Product use issue 25.06 10.22 162 175234 45854 29731228
Dyskinesia 24.82 10.22 57 175339 21777 29755305
Vascular purpura 24.63 10.22 38 175358 1559 29775523
Respiratory depression 24.32 10.22 19 175377 11484 29765598
Nasopharyngitis 24.16 10.22 224 175172 58625 29718457
Hospitalisation 24.15 10.22 156 175240 44163 29732919
Bradycardia 23.68 10.22 526 174870 65000 29712082
Haematoma 23.54 10.22 229 175167 23724 29753358
Haematochezia 23.53 10.22 305 175091 33917 29743165
Skin exfoliation 23.50 10.22 223 175173 22949 29754133
Agitation 23.43 10.22 203 175193 53870 29723212
Pelvic mass 23.41 10.22 13 175383 131 29776951
Eczema 23.29 10.22 146 175250 13223 29763859
Electrolyte depletion 23.24 10.22 15 175381 203 29776879
Rash 23.05 10.22 1358 174038 190531 29586551
Musculoskeletal stiffness 22.36 10.22 121 175275 35760 29741322
Poisoning deliberate 21.95 10.22 4 175392 5900 29771182
Blood lactic acid 21.86 10.22 18 175378 362 29776720
Abnormal loss of weight 21.75 10.22 60 175336 3742 29773340
Blood pressure fluctuation 21.30 10.22 44 175352 17459 29759623
Erythema multiforme 21.28 10.22 98 175298 7887 29769195
Presyncope 21.28 10.22 164 175232 15892 29761190
Coating in mouth 21.20 10.22 10 175386 69 29777013
Pancytopenia 20.93 10.22 649 174747 84403 29692679
Blood electrolytes abnormal 20.79 10.22 26 175370 873 29776209
Azotaemia 20.69 10.22 70 175326 4882 29772200
Generalised tonic-clonic seizure 20.68 10.22 53 175343 19498 29757584
Myocardial infarction 20.57 10.22 569 174827 125056 29652026
Renal function test abnormal 20.54 10.22 44 175352 2335 29774747
Therapeutic product effect decreased 20.44 10.22 94 175302 28982 29748100
Anger 20.36 10.22 21 175375 11099 29765983
Pathogen resistance 20.31 10.22 12 175384 8398 29768684
White blood cell count decreased 20.24 10.22 639 174757 83308 29693774
Base excess decreased 20.18 10.22 14 175382 215 29776867
Oedema 19.83 10.22 358 175038 42635 29734447
Gravitational oedema 19.77 10.22 21 175375 589 29776493
Subacute hepatic failure 19.45 10.22 10 175386 85 29776997
Lymphocytopenia neonatal 19.43 10.22 6 175390 9 29777073
Vomiting 19.40 10.22 1071 174325 218747 29558335
Haematuria 19.18 10.22 369 175027 44465 29732617
Gastrointestinal haemorrhage 19.03 10.22 631 174765 82815 29694267
Product quality issue 19.02 10.22 52 175344 18722 29758360
Erysipelas 18.95 10.22 64 175332 4460 29772622
Post transplant lymphoproliferative disorder 18.87 10.22 4 175392 5302 29771780
Atrial septal defect 18.52 10.22 8 175388 6693 29770389
Dialysis 18.48 10.22 119 175277 10877 29766205
C-reactive protein abnormal 18.36 10.22 5 175391 5588 29771494
Blood count abnormal 18.32 10.22 124 175272 11528 29765554
Skin swelling 18.19 10.22 25 175371 922 29776160
Oligoasthenozoospermia 18.04 10.22 6 175390 13 29777069
Asthenia 18.02 10.22 1517 173879 219773 29557309
Hyponatraemia 17.93 10.22 518 174878 66684 29710398
Blood urea abnormal 17.93 10.22 21 175375 658 29776424
Post-traumatic amnestic disorder 17.88 10.22 8 175388 48 29777034
No adverse event 17.83 10.22 48 175348 17371 29759711
Intestinal haemorrhage 17.80 10.22 50 175346 3151 29773931
Restlessness 17.77 10.22 70 175326 22529 29754553
Withdrawal syndrome 17.65 10.22 24 175372 11226 29765856
Tooth deposit 17.49 10.22 10 175386 107 29776975
Epidermolysis 17.40 10.22 14 175382 272 29776810
Pleural effusion 17.38 10.22 562 174834 73504 29703578
Blood uric acid abnormal 17.35 10.22 9 175387 78 29777004
Electrolyte imbalance 17.26 10.22 121 175275 11379 29765703
Respiratory tract haemorrhage 17.25 10.22 23 175373 824 29776258
Thrombotic microangiopathy 17.24 10.22 15 175381 8595 29768487
Diabetic ketoacidosis 17.17 10.22 43 175353 15943 29761139
Labelled drug-drug interaction medication error 17.08 10.22 113 175283 10425 29766657
Tubulointerstitial nephritis 17.07 10.22 170 175226 17721 29759361
Unresponsive to stimuli 17.07 10.22 88 175308 26331 29750751
Differentiation syndrome 17.05 10.22 27 175369 1133 29775949
Heart rate increased 16.94 10.22 145 175251 38576 29738506
Acute graft versus host disease in skin 16.92 10.22 3 175393 4513 29772569
Dehydration 16.91 10.22 885 174511 122654 29654428
Haemodialysis 16.91 10.22 117 175279 10956 29766126
Arthralgia 16.74 10.22 638 174758 135153 29641929
Febrile infection 16.71 10.22 33 175363 1652 29775430
Crying 16.65 10.22 6 175390 5603 29771479
Graft versus host disease 16.59 10.22 21 175375 10129 29766953
Stag horn calculus 16.59 10.22 4 175392 0 29777082
Pneumonia aspiration 16.29 10.22 142 175254 37638 29739444
Hallucination, auditory 16.27 10.22 20 175376 9769 29767313
Oroantral fistula 16.23 10.22 13 175383 251 29776831
Acute graft versus host disease 16.21 10.22 7 175389 5857 29771225
Orthostatic hypotension 16.18 10.22 213 175183 23766 29753316
Colitis ulcerative 16.15 10.22 38 175358 14396 29762686
Loss of personal independence in daily activities 16.12 10.22 68 175328 21467 29755615
Accidental overdose 16.09 10.22 54 175342 18221 29758861
Diverticulum intestinal 16.08 10.22 49 175347 3233 29773849
Drug therapeutic incompatibility 16.03 10.22 10 175386 127 29776955
Serum ferritin abnormal 16.02 10.22 12 175384 209 29776873
Respiratory fatigue 15.97 10.22 8 175388 64 29777018
Depressed mood 15.91 10.22 49 175347 16980 29760102
Oxygen consumption decreased 15.91 10.22 11 175385 168 29776914
Sarcopenia 15.80 10.22 13 175383 261 29776821
Appendicolith 15.79 10.22 23 175373 896 29776186
Dyspnoea 15.71 10.22 2203 173193 331092 29445990
Portal vein flow decreased 15.64 10.22 5 175391 9 29777073
Mucosal necrosis 15.56 10.22 8 175388 68 29777014
Accidental exposure to product 15.45 10.22 22 175374 10093 29766989
Hyperphosphataemia 15.33 10.22 38 175358 2221 29774861
Sexual dysfunction 15.30 10.22 8 175388 5993 29771089
Unevaluable event 15.29 10.22 116 175280 31669 29745413
Psoriasis 15.28 10.22 167 175229 42339 29734743
Metabolic acidosis 15.24 10.22 306 175090 37155 29739927
Abnormal dreams 15.23 10.22 15 175381 8100 29768982
Hypercalcaemia 15.12 10.22 125 175271 12370 29764712
Mucormycosis 15.03 10.22 6 175390 5262 29771820
Psoriatic arthropathy 14.98 10.22 45 175351 15716 29761366
Aplasia pure red cell 14.96 10.22 69 175327 5557 29771525
Dermatitis allergic 14.77 10.22 70 175326 5702 29771380
Ventricular internal diameter abnormal 14.75 10.22 7 175389 49 29777033
Paranoia 14.74 10.22 23 175373 10165 29766917
Skin reaction 14.73 10.22 59 175337 4466 29772616
Acquired epidermolysis bullosa 14.68 10.22 5 175391 12 29777070
Ichthyosis acquired 14.68 10.22 5 175391 12 29777070
Malignant neoplasm progression 14.66 10.22 317 175079 71970 29705112
Prostate cancer recurrent 14.61 10.22 20 175376 735 29776347
Speech disorder 14.54 10.22 84 175312 24428 29752654
Nephrogenic anaemia 14.53 10.22 36 175360 2103 29774979
Schizophrenia 14.50 10.22 19 175377 9029 29768053
Bronchospasm 14.34 10.22 24 175372 10314 29766768
Tricuspid valve incompetence 14.30 10.22 93 175303 8530 29768552
Genital ulceration 14.12 10.22 10 175386 159 29776923
Immune effector cell-associated neurotoxicity syndrome 14.10 10.22 21 175375 835 29776247
Product prescribing error 14.08 10.22 155 175241 16578 29760504
Crohn's disease 14.08 10.22 4 175392 4348 29772734
Intestinal angioedema 13.96 10.22 10 175386 162 29776920
Dependence on oxygen therapy 13.87 10.22 9 175387 123 29776959
Thrombin time prolonged 13.86 10.22 10 175386 164 29776918
Carcinoma in situ of skin 13.73 10.22 8 175388 89 29776993
Epilepsy 13.71 10.22 66 175330 20103 29756979
Eczema nummular 13.62 10.22 9 175387 127 29776955
Hypertrophy 13.55 10.22 13 175383 322 29776760
Subcutaneous haematoma 13.50 10.22 22 175374 946 29776136
Cardiac failure chronic 13.50 10.22 69 175327 5794 29771288
Hepatosplenomegaly 13.47 10.22 50 175346 3651 29773431
Tachyarrhythmia 13.44 10.22 44 175352 3017 29774065
Vasculitis necrotising 13.38 10.22 17 175379 580 29776502
Human herpesvirus 6 infection 13.35 10.22 33 175363 1925 29775157
Reactive gastropathy 13.21 10.22 10 175386 177 29776905
Decreased gait velocity 13.21 10.22 8 175388 96 29776986
Aptyalism 13.16 10.22 11 175385 226 29776856
Mantle cell lymphoma refractory 13.14 10.22 8 175388 97 29776985
Lip erosion 13.12 10.22 17 175379 592 29776490
Acne 13.00 10.22 22 175374 9414 29767668
Low birth weight baby 12.89 10.22 10 175386 6066 29771016
Oesophagobronchial fistula 12.88 10.22 9 175387 140 29776942
Hypocalcaemia 12.85 10.22 186 175210 21190 29755892
Urate nephropathy 12.80 10.22 5 175391 20 29777062
Scrotal erythema 12.80 10.22 5 175391 20 29777062
Gastritis haemorrhagic 12.71 10.22 24 175372 1162 29775920
Cardioactive drug level increased 12.67 10.22 29 175367 1610 29775472
Drug screen positive 12.60 10.22 5 175391 4402 29772680
Tooth infection 12.59 10.22 62 175334 5129 29771953
Paroxysmal arrhythmia 12.58 10.22 4 175392 7 29777075
Drug abuser 12.57 10.22 5 175391 4396 29772686
Dysarthria 12.53 10.22 116 175280 30374 29746708
Fear 12.51 10.22 28 175368 10797 29766285
Full blood count decreased 12.50 10.22 144 175252 15573 29761509
Acute cutaneous lupus erythematosus 12.48 10.22 7 175389 72 29777010
Heat stroke 12.45 10.22 20 175376 850 29776232
HLA-B*5801 assay positive 12.44 10.22 3 175393 0 29777082
Oesophageal mucosal blister 12.44 10.22 3 175393 0 29777082
Surgical vascular shunt 12.44 10.22 3 175393 0 29777082
Neonatal respiratory distress syndrome 12.41 10.22 4 175392 4008 29773074
Strangury 12.41 10.22 8 175388 108 29776974
Microphthalmos 12.40 10.22 10 175386 195 29776887
Mental disorder 12.35 10.22 39 175357 13410 29763672
Neck pain 12.30 10.22 72 175324 20872 29756210
Hypomagnesaemia 12.29 10.22 150 175246 16448 29760634
Narrow anterior chamber angle 12.24 10.22 4 175392 8 29777074
Treatment noncompliance 12.22 10.22 92 175304 25161 29751921
Transplant rejection 12.19 10.22 22 175374 9184 29767898
Cardiac failure acute 12.17 10.22 94 175302 9115 29767967
Hyperamylasaemia 12.09 10.22 16 175380 569 29776513
Aortic valve stenosis 11.98 10.22 29 175367 1670 29775412
Oral mucosa erosion 11.97 10.22 19 175377 799 29776283
Blood pressure increased 11.96 10.22 325 175071 71603 29705479
Adenovirus infection 11.95 10.22 5 175391 4263 29772819
Device issue 11.94 10.22 17 175379 7799 29769283
Lichenoid keratosis 11.93 10.22 33 175363 2061 29775021
Multiple sclerosis 11.92 10.22 15 175381 7252 29769830
Drug ineffective for unapproved indication 11.89 10.22 29 175367 10851 29766231
Pruritus 11.87 10.22 824 174572 117380 29659702
Brain natriuretic peptide increased 11.87 10.22 51 175345 3984 29773098
Rash pustular 11.72 10.22 59 175337 4924 29772158
Anaphylactic reaction 11.70 10.22 106 175290 27876 29749206
Hypersensitivity vasculitis 11.69 10.22 48 175348 3675 29773407
Rash macular 11.64 10.22 102 175294 10265 29766817
Mantle cell lymphoma 11.62 10.22 27 175369 1514 29775568
Hypocoagulable state 11.61 10.22 20 175376 901 29776181
Rectal haemorrhage 11.54 10.22 277 175119 34662 29742420
Injection site reaction 11.51 10.22 29 175367 10731 29766351
Hallucination 11.49 10.22 210 175186 48849 29728233
Feeling abnormal 11.48 10.22 249 175147 56507 29720575
Injection site erythema 11.42 10.22 42 175354 13792 29763290
Obsessive-compulsive disorder 11.36 10.22 5 175391 4136 29772946
Rhinorrhoea 11.33 10.22 73 175323 20681 29756401
Rash vesicular 11.22 10.22 36 175360 2442 29774640
Rash morbilliform 11.02 10.22 36 175360 2466 29774616
Actinic keratosis 10.96 10.22 46 175350 3557 29773525
Diverticulum intestinal haemorrhagic 10.95 10.22 32 175364 2063 29775019
Catatonia 10.93 10.22 6 175390 4374 29772708
Tremor 10.91 10.22 347 175049 75016 29702066
Atrioventricular block complete 10.91 10.22 86 175310 8391 29768691
Mastitis 10.89 10.22 9 175387 182 29776900
Injection site pruritus 10.89 10.22 10 175386 5582 29771500
Dyspnoea exertional 10.84 10.22 278 175118 35152 29741930
Jaundice cholestatic 10.79 10.22 54 175342 4497 29772585
Granulomatous liver disease 10.70 10.22 14 175382 492 29776590
Brain oedema 10.66 10.22 37 175359 12361 29764721
Hypoaesthesia 10.65 10.22 239 175157 53991 29723091
Aortic dissection 10.63 10.22 35 175361 2407 29774675
Underdose 10.60 10.22 36 175360 12105 29764977
Lymphadenopathy 10.55 10.22 201 175195 24175 29752907
Interstitial lung disease 10.53 10.22 442 174954 59755 29717327
Hypoglycaemia 10.49 10.22 381 175015 50600 29726482
Left ventricular enlargement 10.48 10.22 15 175381 575 29776507
Cancer fatigue 10.42 10.22 5 175391 36 29777046
Mucosal haemorrhage 10.40 10.22 25 175371 1433 29775649
Memory impairment 10.40 10.22 154 175242 37020 29740062
Glossopharyngeal nerve paralysis 10.38 10.22 3 175393 3 29777079
Purpura non-thrombocytopenic 10.38 10.22 3 175393 3 29777079
Glomerular filtration rate decreased 10.38 10.22 107 175289 11255 29765827
Transfusion reaction 10.37 10.22 19 175377 899 29776183
Mood swings 10.30 10.22 18 175378 7608 29769474
Small for dates baby 10.28 10.22 3 175393 3205 29773877
Influenza like illness 10.27 10.22 98 175298 25507 29751575
Sleep inertia 10.24 10.22 4 175392 16 29777066
Amnesia 10.22 10.22 92 175304 24229 29752853

Pharmacologic Action:

SourceCodeDescription
ATC M04AA01 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations inhibiting uric acid production
ATC M04AA51 MUSCULO-SKELETAL SYSTEM
ANTIGOUT PREPARATIONS
ANTIGOUT PREPARATIONS
Preparations inhibiting uric acid production
FDA MoA N0000000206 Xanthine Oxidase Inhibitors
FDA EPC N0000175698 Xanthine Oxidase Inhibitor
MeSH PA D000963 Antimetabolites
MeSH PA D000975 Antioxidants
MeSH PA D018501 Antirheumatic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D016166 Free Radical Scavengers
MeSH PA D006074 Gout Suppressants
MeSH PA D009676 Noxae
CHEBI has role CHEBI:35221 antimetabolite
CHEBI has role CHEBI:35634 xanthine oxidase inhibitors
CHEBI has role CHEBI:35845 gout suppressants
CHEBI has role CHEBI:48578 free-radical scavenger

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperuricemia indication 35885006 DOID:1920
Articular gout indication 48440001 DOID:13189
Gout indication 90560007 DOID:13189
Uric acid renal calculus indication 274401005
Calcium renal calculus indication 427649000
Uric Acid Nephropathy Gout indication
Chemotherapy-Induced Hyperuricemia indication
Recurrent Calcium Renal Calculi indication
Adjunctive treatment for bipolar disorder off-label use 13746004 DOID:3312
Deficiency of adenine phosphoribosyltransferase off-label use 124274002 DOID:0060350
Deficiency of ribose-phosphate pyrophosphokinase off-label use 124343001
Neonatal Phosphoribosylpyrophosphate Synthetase Superactivity off-label use
Dehydration contraindication 34095006
Chronic heart failure contraindication 48447003
Hypersensitivity angiitis contraindication 60555002
Impaired renal function disorder contraindication 197663003
Disease of liver contraindication 235856003 DOID:409

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.52 acidic
pKa2 9.43 acidic
pKa3 1.45 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Xanthine dehydrogenase/oxidase Enzyme INHIBITOR Ki 5.15 CHEMBL CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Enzyme WOMBAT-PK
Xanthine dehydrogenase/oxidase Enzyme Ki 6 CHEMBL
Xanthine dehydrogenase/oxidase Enzyme IC50 6.12 CHEMBL

External reference:

IDSource
63CZ7GJN5I UNII
4017895 VUID
N0000146247 NUI
D00224 KEGG_DRUG
17795-21-0 SECONDARY_CAS_RN
C0002144 UMLSCUI
CHEBI:40279 CHEBI
CHEMBL1467 ChEMBL_ID
CHEMBL1200477 ChEMBL_ID
DB00437 DRUGBANK_ID
D000493 MESH_DESCRIPTOR_UI
135401907 PUBCHEM_CID
1731 INN_ID
6795 IUPHAR_LIGAND_ID
203600 RXNORM
1590 MMSL
1816 MMSL
4150 MMSL
8255 MMSL
8256 MMSL
d00023 MMSL
001084 NDDF
005000 NDDF
25246002 SNOMEDCT_US
387135004 SNOMEDCT_US
425496004 SNOMEDCT_US
4017895 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Allopurinol sodium HUMAN PRESCRIPTION DRUG LABEL 1 0143-9533 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 500 mg INTRAVENOUS ANDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0137 TABLET 100 mg ORAL ANDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0378-0181 TABLET 300 mg ORAL ANDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0591-5543 TABLET 100 mg ORAL NDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0591-5544 TABLET 300 mg ORAL NDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0603-2115 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0603-2116 TABLET 300 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-1592 TABLET 100 mg ORAL ANDA 21 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-1593 TABLET 300 mg ORAL ANDA 21 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-8321 TABLET 100 mg ORAL NDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0615-8385 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6571 TABLET 100 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-6572 TABLET 300 mg ORAL ANDA 12 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 0904-7041 TABLET 100 mg ORAL ANDA 16 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-545 TABLET 100 mg ORAL ANDA 17 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-547 TABLET 300 mg ORAL ANDA 17 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 10544-911 TABLET 300 mg ORAL ANDA 19 sections
Allopurinol Human Prescription Drug Label 1 16714-041 TABLET 100 mg ORAL ANDA 21 sections
Allopurinol Human Prescription Drug Label 1 16714-042 TABLET 300 mg ORAL ANDA 21 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16729-134 TABLET 100 mg ORAL ANDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 16729-135 TABLET 300 mg ORAL ANDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 21695-246 TABLET 300 mg ORAL ANDA 21 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 21695-836 TABLET 100 mg ORAL ANDA 21 sections
Allopurinol Human Prescription Drug Label 1 23155-693 TABLET 100 mg ORAL ANDA 19 sections
Allopurinol Human Prescription Drug Label 1 23155-694 TABLET 300 mg ORAL ANDA 19 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 29300-349 TABLET 100 mg ORAL ANDA 15 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 29300-350 TABLET 300 mg ORAL ANDA 15 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 33261-597 TABLET 300 mg ORAL NDA 20 sections
Allopurinol HUMAN PRESCRIPTION DRUG LABEL 1 33261-810 TABLET 100 mg ORAL NDA 20 sections
ALLOPURINOL HUMAN PRESCRIPTION DRUG LABEL 1 42549-500 TABLET 100 mg ORAL ANDA 20 sections